wave5-sponsor
No description yet: the sentence for this tag has not been written. 8 records carry it: 8 companies.
8 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
4SC Planegg-Martinsried, DE 4SC is a listed German biotechnology company founded in 1997 in Planegg-Martinsried, near Munich. It applied to the EMA for its HDAC inhibitor resminostat (Kinselby) in advanced mycosis fungoides and Sézary syndrome and received a negative opinion in May 2025. | Cutaneous T-cell lymphoma | none | none | ||
Ambrx La Jolla, California, US Ambrx is a La Jolla, California biotechnology company founded in 2003 whose HER2 antibody-drug conjugate ARX788 is in OnCo's phase 3 ACE-Breast-02 trial (with Zhejiang Medicine, in China) and the global phase 2 ACE-Breast-03 trial after trastuzumab deruxtecan. | HER2-positive breast cancer | none | none | ||
Artios Pharma Cambridge, GB Artios Pharma is a Cambridge, UK biotechnology company that leads two cancer trials in OnCo, testing its DNA damage response inhibitors ART0380 (ATR) and ART6043 (DNA polymerase theta) in advanced solid tumours. | Ovarian cancer, Endometrial cancer, Colorectal cancer | none | none | ||
Criterium Saratoga Springs, New York, US Criterium is a US company in Saratoga Springs, New York, that is the lead sponsor of four cancer trials in OnCo, all testing other makers' drugs: fruquintinib with TAS-102 in colorectal cancer and tucatinib, alpelisib or palbociclib combinations in breast cancer. | Colorectal cancer, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer | none | none | ||
Grünenthal Aachen, DE Grünenthal is a German pharmaceutical company founded in 1946 in Aachen. In OnCo it is the marketing authorisation holder of PecFent, a fentanyl nasal spray authorised in the EU for breakthrough pain in adults on maintenance opioids for chronic cancer pain. | none | none | none | ||
Immunovaccine (IMV) Halifax, Nova Scotia, CA Immunovaccine (IMV) is a Canadian biotechnology company founded in 2000 in Halifax, Nova Scotia, whose survivin-targeted immunotherapy DPX-Survivac is tested with pembrolizumab and low-dose cyclophosphamide in two OnCo trials, in relapsed diffuse large B-cell lymphoma and in selected solid tumours. | Diffuse large B-cell lymphoma, Ovarian cancer, Hepatocellular carcinoma | none | none | ||
Nerviano Medical Sciences Nerviano, IT Nerviano Medical Sciences is an Italian drug-discovery company founded in 2004 in Nerviano, near Milan, that leads two cancer trials in OnCo: the PARP1-selective inhibitor atamparib in advanced solid tumours and NMS-03305293 with temozolomide in recurrent glioblastoma. | Non-small-cell lung cancer, Glioma & glioblastoma | none | none | ||
Qurient Seongnam, KR Qurient is a South Korean biotechnology company in Seongnam that leads two cancer trials in OnCo, testing the selective CDK7 inhibitor Q901 and the Axl/Mer/CSF1R inhibitor Q702, each with pembrolizumab, in advanced solid tumours. | Cervical cancer | none | none |